Literature DB >> 26646041

Examining why patients with attention-deficit/hyperactivity disorder lack adherence to medication over the long term: a review and analysis.

Elliot Frank1, Cristina Ozon, Vinitha Nair, Karandeep Othee.   

Abstract

OBJECTIVE: To investigate the reasons why patients with attention-deficit/hyperactivity disorder (ADHD) adhere poorly to medications over the long term (≥ 1 year). DATA SOURCES: PubMed was reviewed for studies between 1997 and January 2015 citing the reasons for medication nonadherence using these main keywords: ADHD, amphetamine, methylphenidate, atomoxetine, guanfacine, clonidine, long term, and adverse effects. Non-English language articles were excluded as were those that had a follow-up of < 1 year. STUDY SELECTION: Of 1,137 entries, 41 published articles citing reasons for subject withdrawal from treatment were included. None were included for clonidine. DATA EXTRACTION: Similar reasons for drug or study withdrawal were grouped together for analysis using a normalized numerical average, while unique reasons were analyzed individually.
RESULTS: Reasons for discontinuing Food and Drug Administration (FDA)-approved medication after 1 year included "own wish/remission/don't need" (19.9%; 95% CI, 9.0-30.80), "withdrew consent" (16.2%; 95% CI, 10.0-22.5), "adverse effects" (15.1%; 95% CI, 10.4-19.8) and "suboptimal effect" (14.6%; 95% CI, 8.5-20.6), with the most common adverse event being "reduction in weight/appetite" (19.2%; 95% CI, 5.1-33.4). Other important factors included age, long- versus short-acting medication, psychosocial stressors, and "stop feeling like him/herself" on medication.
CONCLUSIONS: The reasons why patients do not adhere to stimulant medication remain poorly studied and understood, especially over the long term. Standardizing the way studies evaluate patients who stop treatment and including more qualitative measures should lead to better treatment outcome and adherence to medication over the long term. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26646041     DOI: 10.4088/JCP.14r09478

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

1.  Generalized structural equation modeling: Symptom heterogeneity in attention-deficit/hyperactivity disorder leading to poor treatment efficacy.

Authors:  Ruu-Fen Tzang; Yue-Cune Chang
Journal:  World J Psychiatry       Date:  2022-06-19

2.  Predictors of Changes in Height, Weight, and Body Mass Index After Initiation of Central Nervous System Stimulants in Children with Attention Deficit Hyperactivity Disorder.

Authors:  James G Waxmonsky; William E Pelham; Raman Baweja; Daniel Hale; William E Pelham
Journal:  J Pediatr       Date:  2021-09-25       Impact factor: 4.406

3.  Strategies for improving ADHD medication adherence.

Authors:  Kelly I Kamimura-Nishimura; William B Brinkman; Tanya E Froehlich
Journal:  Curr Psychiatr       Date:  2019-08

4.  Comparative efficacy of targeted structural patterns of electroencephalography neurofeedback in children with inattentive or combined attention deficit hyperactivity disorder.

Authors:  Feng-Hua Wang; Li-Yan Sun; Xiao-Mei Cui; He-Dan Zhao; Ling-Fei Yang; Zheng Wang; Tong-Kun Shi
Journal:  Brain Behav       Date:  2022-04-24       Impact factor: 3.405

5.  Immediate and Sustained Effects of Neurofeedback and Working Memory Training on Cognitive Functions in Children and Adolescents with ADHD: A Multi-Arm Pragmatic Randomized Controlled Trial.

Authors:  John Hasslinger; Ulf Jonsson; Sven Bölte
Journal:  J Atten Disord       Date:  2022-01-16       Impact factor: 3.196

6.  Eliciting preferences for continuing medication among adult patients and parents of children with attention-deficit hyperactivity disorder.

Authors:  Muhammad Umair Khan; Camila Balbontin; Michiel C J Bliemer; Parisa Aslani
Journal:  Health Expect       Date:  2022-03-10       Impact factor: 3.318

7.  Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.

Authors:  David B Clemow; Allen W Nyhuis; Rebecca L Robinson
Journal:  CNS Neurosci Ther       Date:  2016-07-31       Impact factor: 5.243

8.  Managing Complexity: Exploring Decision Making on Medication by Young Adults with ADHD.

Authors:  Louise C Druedahl; Sofia Kälvemark Sporrong
Journal:  Pharmacy (Basel)       Date:  2018-04-19

Review 9.  Impact of CNS Stimulants for Attention-Deficit/Hyperactivity Disorder on Growth: Epidemiology and Approaches to Management in Children and Adolescents.

Authors:  Raman Baweja; Daniel E Hale; James G Waxmonsky
Journal:  CNS Drugs       Date:  2021-07-23       Impact factor: 5.749

10.  Bright light therapy versus physical exercise to prevent co-morbid depression and obesity in adolescents and young adults with attention-deficit / hyperactivity disorder: study protocol for a randomized controlled trial.

Authors:  Jutta S Mayer; Katharina Hees; Juliane Medda; Oliver Grimm; Philip Asherson; Mariano Bellina; Michael Colla; Pol Ibáñez; Elena Koch; Antonio Martinez-Nicolas; Adrià Muntaner-Mas; Anna Rommel; Nanda Rommelse; Saskia de Ruiter; Ulrich W Ebner-Priemer; Meinhard Kieser; Francisco B Ortega; Johannes Thome; Jan K Buitelaar; Jonna Kuntsi; J Antoni Ramos-Quiroga; Andreas Reif; Christine M Freitag
Journal:  Trials       Date:  2018-02-26       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.